A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients

Phase 3

Terminated

Conditions: Pulmonary Embolism
Venous Thromboembolism

Interventions: Drug: dalteparin injection

Registration Number: NCT00876915

Lead Sponsor: University of Rochester

Brief Summary: Some cancer patients starting a new chemotherapy regimen are likely to develop blood clots, also known as venous thromboembolism (VTE). Blood clots can cause symptoms and can occasionally be life-threatening. The purpose of this study is to determine if a daily injection of a blood-thinner, dalteparin, for 12 weeks can safely and effectively reduce the frequency of blood clots. Dalteparin is currently approved for prevention of blood clots following surgery and in hospitalized patients but not specifically for cancer outpatients.

Detailed Description: VTE is an increasingly frequent complication of cancer and anti-cancer therapies. It is associated with increased mortality and other significant adverse consequences. Risk factors for VTE in the cancer population have been identified, and multiple studies have also shown that VTE can be prevented in high-risk populations with the use of thromboprophylaxis. This study evaluated the safety and efficacy of prophylaxis in a high-risk subgroup of cancer patients identified by a validated risk model developed by us previously called the "Khorana Score." Correlative studies evaluated the value of tissue factor as a predictive biomarker of VTE. The purpose of this study was to conduct a prospective, randomized clinical trial comparing the safety and efficacy of prophylaxis with dalteparin to no treatment in reducing VTE in high-risk ambulatory cancer patients initiating chemotherapy and to establish the value of TF as a predictive marker for VTE in ambulatory cancer patients receiving chemotherapy.

PHACS was a randomized multi-center clinical trial. Eligible patients were enrolled and underwent baseline screening ultrasonography of the lower extremities to rule out pre-existing DVT and a chest CT scan to rule out PE. If negative, patients were then randomized to receive either dalteparin 5000 units subcutaneously daily or observation for a study period of 12 weeks. The first day of dalteparin prophylaxis coincided with the first day of initiation of a new systemic chemotherapy regimen. The patients were seen every 4 weeks (±1 week) at the time of regularly scheduled chemotherapy cycle visits for serial ultrasonography of lower extremities during study period (i.e. at 4, 8 and 12 weeks.) A chest CT scan was performed at 12 weeks. Compliance was measured by asking patients about missed doses at these 4-weekly visits as well as by asking patients to fill an injection diary.

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 218

Inclusion Criteria

A histologic diagnosis of malignancy;
At planned initiation of a new systemic chemotherapy regimen (including patients starting on first chemotherapy or patients previously treated but starting on a new regimen);
A risk score for VTE ≥3 [assign score of 2 for very high risk sites of cancer (stomach, pancreas), score of 1 for high risk site (lung, lymphoma, gynecologic, bladder, testicular) and score of 0 for all other sites], hemoglobin <10 g/dL or planned use of erythropoiesis stimulating agents, platelet count ≥350,000/mm3, total leukocyte count > 11,000/mm3 or body mass index ≥ 35 kg/m2]. Any counts meeting criteria drawn within 2 weeks prior to enrollment are considered acceptable.
Age 18 years or older
Provide written, informed consent.

Exclusion Criteria

Active bleeding or at high risk of serious bleeding complication in the opinion of the investigator
Diagnosis of primary brain tumor multiple myeloma, leukemia, or myelodysplastic syndrome
Planned stem cell transplant
Life expectancy < 6 months
Known allergy to heparin or LMWH
Patient or caregiver incapable of daily self-injection
Acute or chronic renal insufficiency with creatinine clearance < 30 mL/min
History of heparin-induced thrombocytopenia
Allergy to contrast agents
Pregnancy
Need for anticoagulant therapy
Platelet count < 75,000/mm3

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
High Risk for VTE recieving dalteparin	dalteparin injection	Patients assigned at random to receive prophylactic dalteparin injections

Primary Outcome Measures

Name	Time	Method
Percentage of Patients Who Experienced Clinically Significant Bleeding Events.	13 weeks	The percentage of patients who experienced a clinically significant bleeding event were recorded (including major and clinically significant non-major bleeding) over 13 weeks (12 weeks of study and an additional week of observation). Major bleeding was defined as being clinically overt and satisfying one of the following: decrease in hemoglobin of 2.0 g/dL, leading to transfusion of 2 or more units of blood or packed red cells, occurring in a critical site (intraocular, spinal/epidural, intracranial, retroperitoneal, or pericardial) or leading to death. Clinically significant non-major bleeding was defined as clinically overt, not meeting criteria for major bleeding and with one of the following characteristics: multiple-source, spontaneous hematoma \> 25 cm², epistaxis \> 5 mins, macroscopic hematuria not related to instrumentation, spontaneous rectal bleeding, gingival bleeding \> 5 mins, hemoptysis, hematemesis or prolonged bleeding (\> 5 minutes) after venipuncture.
Percentage of Patients With Venous Thromboembolisms	12 weeks	The percentage of patients who developed a Venous thromboembolism were recorded within 12 weeks following randomization including all adjudicated occurrences of symptomatic DVT, PE and upper extremity thrombus as well as all asymptomatic DVT and PE detected by lower extremity ultrasonography and chest CT.

Secondary Outcome Measures

Name	Time	Method
The Value of D-Dimer at Baseline Prior to Chemotherapy in Ambulatory Cancer Patients	baseline value of D-Dimer	Blood samples were obtained to measure the value of D-Dimer at baseline compared between high risk for VTE and low risk for VTE ambulatory cancer patients
The Value of Human F12 at Baseline Prior to Chemotherapy in Ambulatory Cancer Patients	baseline value of Human F12	Blood samples were obtained to measure the value of Human F12 at baseline compared between high risk for VTE and low risk for VTE ambulatory cancer patients
The Value of Tissue Factor (TF) at Baseline Prior to Chemotherapy in Ambulatory Cancer Patients	baseline value of tissue factor	Blood samples were obtained to measure the value of Tissue Factor at baseline compared between high risk for VTE and low risk for VTE ambulatory cancer patients.
The Value of Tissue Factor Pathway Inhibitor (TFPI) at Baseline Prior to Chemotherapy in Ambulatory Cancer Patients	baseline value of TFPI	Blood samples were obtained to measure the value of TFPI at baseline compared between high risk for VTE and low risk for VTE ambulatory cancer patients
The Value of Factor VIIa (FVIIa) at Baseline Prior to Chemotherapy in Ambulatory Cancer Patients	baseline value of FVIIa	Blood samples were obtained to measure the value of FVIIa at baseline compared between high risk for VTE and low risk for VTE ambulatory cancer patients
The Value of Thrombin Antithrombin (TAT) at Baseline Prior to Chemotherapy in Ambulatory Cancer Patients	baseline value of TAT	Blood samples were obtained to measure the value of TAT at baseline compared between high risk for VTE and low risk for VTE ambulatory cancer patients

Trial Locations

Locations (7): University of California, Davis
🇺🇸
Sacramento, California, United States
Rochester General Hospital
🇺🇸
Rochester, New York, United States
Duke University School of Medicine
🇺🇸
Durham, North Carolina, United States
Cleveland Clinic
🇺🇸
Cleveland, Ohio, United States
Roswell Park Cancer Institute
🇺🇸
Buffalo, New York, United States
University of Rochester Medical Center
🇺🇸
Rochester, New York, United States
Ottawa Hospital Research Institute (OHRI)
🇨🇦
Ottawa, Ontario, Canada